Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mRNA-1010 seasonal influenza vaccine in adults 50 years and older
2022-001638-12Phase 3Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of mRNA-1010 in influenza (2 arms), sponsored by Moderna Inc. Primary endpoint: Solicited local and systemic adverse reactions. Started Jul 2022; status: completed.
02
Drugs
mRNA-1010
03
Conditions
influenza
Beyond the preview
Go deeper on 2022-001638-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001638-12.